+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Orenitram"

Fibrate Drugs Market Report 2025 - Product Thumbnail Image

Fibrate Drugs Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
Pulmonary Arterial Hypertension Market Size, Share & Trends Analysis Report by Drug Class, by Type (Branded, Generics), by Route of Administration (Oral, Intravenous/ subcutaneous, Inhalational), by Region, and Segment Forecasts, 2022-2030 - Product Thumbnail Image

Pulmonary Arterial Hypertension Market Size, Share & Trends Analysis Report by Drug Class, by Type (Branded, Generics), by Route of Administration (Oral, Intravenous/ subcutaneous, Inhalational), by Region, and Segment Forecasts, 2022-2030

  • Report
  • January 2022
  • 150 Pages
  • Global
From
Pulmonary Arterial Hypertension Market Insight, Epidemiology and Market Forecast - 2034 - Product Thumbnail Image

Pulmonary Arterial Hypertension Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • January 2024
  • 250 Pages
  • Global
From
Orenitram Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

Orenitram Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • December 2022
  • 30 Pages
  • Global
From
Disease Analysis: Pulmonary Hypertension - Product Thumbnail Image

Disease Analysis: Pulmonary Hypertension

  • Drug Pipelines
  • April 2021
  • 78 Pages
  • Global
Tyvaso - Product Thumbnail Image

Tyvaso

  • Report
  • October 2018
  • 17 Pages
  • Global
From
  • 6 Results (Page 1 of 1)
Loading Indicator

Orenitram (treprostinil) is a cardiovascular drug used to treat pulmonary arterial hypertension (PAH). It is a prostacyclin analogue that works by relaxing the blood vessels in the lungs, allowing for improved blood flow and oxygen delivery. Orenitram is administered orally, and is available in both immediate-release and extended-release formulations. It is typically used in combination with other PAH treatments, such as endothelin receptor antagonists and phosphodiesterase-5 inhibitors. Orenitram is marketed by United Therapeutics Corporation, and is available in the United States, Canada, and Europe. Other companies that produce cardiovascular drugs include GlaxoSmithKline, Bayer, and Novartis. Show Less Read more